Drug Overview
Fasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes them. Elevated eosinophils are related to the cause and severity of asthma, as well as to asthma exacerbations. This mechanism of action differs from Nucala (mepolizumab; GlaxoSmithKline) and Cinqair (reslizumab; Teva), which bind to the IL-5 ligand, and this is proposed to lead to a faster onset of action.
Fasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes them. Elevated eosinophils are related to the cause and severity of asthma, as well as to asthma exacerbations. This mechanism of action differs from Nucala (mepolizumab; GlaxoSmithKline) and Cinqair (reslizumab; Teva), which bind to the IL-5 ligand, and this is proposed to lead to a faster onset of action.
Table of Contents
Product ProfilesFasenra: Asthma
benralizumab: Chronic obstructive pulmonary disease (COPD)
List of Figures
Figure 1: Fasenra for asthma - SWOT analysis
Figure 2: Drug assessment summary of Fasenra in asthma
Figure 3: Drug assessment summary of Fasenra in asthma
Figure 4: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Fasenra drug profile
Table 2: Fasenra Phase III trials in asthma
Table 3: Ongoing Phase III trials for Fasenra in asthma
Table 4: Fasenra sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Benralizumab drug profile
Table 6: Phase III clinical trials for benralizumab in COPD
Table 7: Phase IIa clinical trial data for benralizumab in COPD
